Commenting on this acquisition, Peter Moriarty, the Chairman and co-founder of the company, stated, "This is an important milestone in the development of Prismic Pharmaceuticals. Having gained access to the robust patents through the acquisition of Scarista, Prismic is planning to partner with one or more pharmaceutical companies in order to maximize the considerable commercial opportunity the patents offer in the CNS area."
"There is already an established body of research and clinical experience indicating the therapeutic benefits and safety of highly purified forms of EPA and DHA for the treatment of cardiovascular disease. There is also similar data relating to their use in the treatment of a number of CNS disorders," Moriarty added. "Prismic, therefore, believes that any company licensing our IP will have the opportunity to bring patent-protected formulations to market relatively expeditiously."